Clinical trial · Observational
Analysis the Positive Rate of Tumor Markers Among Physical Examination Population
Analysis the Positive Status of Tumor Markers Among Physical Examination Population in a Tertiary Grade A Class Hospital
NCT05165147CI-TRIAL-00055621completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To analyze the positive rate of tumor markers (TM) among health examination population in a tertiary grade A class hospital, compare the differences between different age and sex groups, and explore the possible influencing factors of TM positive.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Tumor | Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| no intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- physical examination population
- description
- From January 2019 to December 2019, who underwent physical examination in Peking University Third Hospital were included in the study.
- interventionNames
- Other: no intervention
Primary outcomes (12)
- measure
- the positive rate of carcinoembryonic antigen（CEA）
- timeFrame
- 2019.01.01-2019.12.31
- description
- The proportion of abnormal CEA in physical examination population was calculated. The range of normal value ： CEA≤5 ng/mL.
- measure
- the positive rate of α-fetoprotein（AFP）
- timeFrame
- 2019.01.01-2019.12.31
- description
- The proportion of abnormal AFP in physical examination population was calculated. The range of normal value ： AFP≤20 ng/mL.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Those who have taken a physical examination and performed at least one TM test Exclusion Criteria: * Basic information is missing and cannot be retrieved * The patient was diagnosed with malignant tumor before examination * Those who have not done any TM tests
References
Publications (1)
- RESULTWelch HG, Albertsen PC. Reconsidering Prostate Cancer Mortality - The Future of PSA Screening. N Engl J Med. 2020 Apr 16;382(16):1557-1563. doi: 10.1056/NEJMms1914228. No abstract available. PMID 32294352